Establishment of patient-derived cancer model
Pre-clinical examinations require the in vitro evaluation system such as patient-derived cancer models. We have made a collaborative system to create patient-derived xenograft, primary-tissue culture cells, and cell line from tumor tissues. The established models are used for drug screening for the purpose of re-location of anti-cancer drugs to rare cancers. The global gene and protein data are obtained from the established models, and organized in the database. By combining the omics data with clinical and pathological data, we will be able to understand the molecular basis of cancer models.
Screening of anti-cancer compound
We are establishing a high throughput screening system for anti-cancer compound against the established cell lines. Integrating the inhibition data and the omics data, we will be able to predict the sensitivity of cancer cells to certain compounds.
Establishment of novel patient-derived cancer models
We have a series of protocols to establish PDX, primary-tissue culture cells, and cell lines from surgically resected tumor tissues. We started to establish the patient-derived cancer model since 2014. We challenged tumor tissues of more than 200 sarcoma cases, and established 40 PDX models and 30 cell lines. Application of the established models for cancer research is our next challenge.
Recent results: establishment and characterization of patient-derived cancer models of CIC-DUX4 sarcoma
CIC-DUX4 sarcoma exhibits similar histological appearance to Ewing’s sarcoma. However, CIC-DUX4 sarcoma has its own unique fusion gene. The CIC-DUX4 sarcoma exhibits aggressive clinical course, and novel treatments have long been required. We successfully established patient-derived xenografts and cell lines from tumor tissues of a patient with CIC-DUX4 sarcoma.
Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F, Shiozawa K, Qiao Z, Arai Y, Shibata T, Araki Y, Endo M, Kawai A, Kondo T. Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. Sci Rep. 2017 Jul 5;7(1):4712.
PubMed PMID: 28680140.
Screening of anti-cancer compounds
For the re-location study of rare cancers, we established high throughput screening system using the panel of patient-derived cell lines and an automated liquid handling machine. Integration of screening results and omics data will further our understanding of molecular backgrounds of inhibitory effects of novel anti-cancer compounds.
We will be able to facilitate clinical trials using a patient-derived cancer models and high throughput screening system. Patient-derived cancer models are essential tools to evaluate the anti-cancer effects of novel compounds. We are going to share our research resource for pre-clinical studies.
Our PDX models, primary-tissue culture cells, and cell lines can be used in the collaboration studies. We will provide our research resource to academic researchers and industrial companies. If you are interested in the patient-derived cancer models developed in our laboratory, please contact us. We will provide an opportunity to work with specialists of cancer research in the collaboration study.